However, they have only exhibited minimal effects on histopathology in NAFLD.[50] Pioglitazone, a PPARγ selective agonist, has been confirmed effective in treating patients with NAFLD and type 2 diabetes. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.